Clinical Trial Update: Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils [Phase 4]

View source ↗

Summary

Phase 4 trial assessed whether basophil biomarker responses (anti-IgE antibodies or Syk expression) can predict how patients with allergic asthma respond to oma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Asthma

Drugs mentioned

• Omalizumab (Omalizumab)

Snippet

Sponsor: Johns Hopkins University | Conditions: Allergic Asthma | Phase 4 | Status: COMPLETED | Results posted: 2017-12-11